Press Releases

Investors & Media

 
Press Releases
  Date Title and Summary View
May 15, 2017
Advancing a new potential therapeutic paradigm for the treatment of negative symptoms, a key unmet need in schizophrenia and other brain diseases Company to host conference call on May 16, 2017 at 10:30 a.m. eastern timeWALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutic...
May 15, 2017
Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 and primary endpoint of improvement in negative symptoms of schizophrenia Planned initiation of MIN-101 Phase 3 development in second half of 2017 WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Following a recent "end-of-Phase 2" meeting with the U.S. Food and Drug Admi...
May 4, 2017
WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2017. "We recently had a meet...
Apr 27, 2017
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2017 on Thursday, May...
Mar 21, 2017
WALTHAM, Mass., March 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today announced the recent exercise of warrants held by certain institutional stockholders...
Mar 13, 2017
Multiple positive data readouts during 2016 provide foundation for initiation of advanced clinical trials with three product candidates in 2017   Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company ...
Mar 6, 2017
Management to host conference call WALTHAM, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the fou...
Feb 28, 2017
WALTHAM, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference on March 7 at 10:40 a.m. Eas...
Feb 21, 2017
WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will host a Research and Development Day to highlight unmet needs, including negative symptoms and cognitive impairment, and ...
Jan 20, 2017
WALTHAM, Mass., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the results of additional data analyses related to cognitive function from its 12-week, randomized, double-bl...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase